Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 30th Apr 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue £m
Operating Profit £m
Net Profit £m
EPS Reported p
EPS Normalised p
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps p
Capex ps p
Free Cashflow ps p
Dividend ps p
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc £m
Working Capital £m
Net Fixed Assets £m
Net Debt £m
Book Value £m
Average Shares m
Book Value ps p -4.2%

FINANCIAL BRIEF: For the six months ended 31 October 2014, Scancell Holdings Plc revenues was not reported. Net loss increased 13% to L1.3M. Basic Earnings per Share excluding Extraordinary Items remained flat at -L0.01. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Oct '14) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
30th Apr 2015
30th Apr 2016

Price Target: 0.79
(+177.21% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (£) (p) (p) (£) (p) (p)
Consensus Estimate
1m Change
3m Change
1 brokers Broker Consensus Trend
Broker Recommendations for Scancell Holdings
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 0 0 0 1 0

Named Brokers and Analysts
Panmure Gordon Mike Mitchell , Cenkos Securities Navid Malik ,

Profile Summary

Scancell Holdings PLC is a United Kingdom-based pharmaceutical company. The Company’s principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms. The Company’s cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase II clinical trials. SCIB1 is a plasmid Deoxyribonucleic Acid (DNA), which encodes a human antibody molecule engineered to express a melanoma antigen called Tyrosinase-Related Protein 2 (TRP2) plus two helper T cell epitopes. The product pipeline of the Company consists of SCIB2, which stimulates immune responses to the lung cancer antigen NY-ESO-1.

Directors: Lindy Durrant (CEO) , Richard Goodfellow (CCE) , Sally Adams (OTH) 53, David Evans (NEC) 54, Katherine Cornish-Bowden (NED) 44, Matthew Frohn (NED) ,

No. of Employees: 7 No. of Shareholders: n/a

Last Annual April 30th, 2014
Last Interim October 31st, 2014
Incorporated April 14, 2008
Shares in Issue 224,950,683
Free Float 178.1m (79.2%)
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Intl-aim All Share ,
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?

SCLP Share Price Performance SCLPQuote
-0.9  -3.1%
Traded 4:16pm · Minimum 15 min delayed · NMS: 15.0k

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy SCLP

Access SCLP Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis